Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Executive Director | 5.43M | -- | 1959 |
| Dr. Aradhana Sarin M.D. | CFO & Executive Director | 3M | -- | 1974 |
| Ms. Pam P. Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | -- | -- | 1970 |
| Mr. Andrew P. Barnett | Head of Investor Relations | -- | -- | -- |
| Mr. Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | -- | -- | -- |
| Gonzalo Vina | Head of Global Media Relations | -- | -- | -- |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit | -- | -- | -- |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Research & Development | -- | -- | 1966 |
| Ms. Iskra Reic | Executive Vice President of International | -- | -- | -- |
| Mr. David Fredrickson | Executive Vice-President of Oncology Business Unit | -- | -- | -- |
AstraZeneca PLC
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 89,900
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Corporate Governance
Upcoming Events
February 6, 2025 at 7:00 AM UTC
AstraZeneca PLC Earnings Date
Recent Events
August 9, 2024 at 12:00 AM UTC
Ex-Dividend Date